Paper
PET/CT in Non-Hodgkin Lymphoma: An Update.
Published Dec 1, 2022 · L. Zanoni, D. Bezzi, C. Nanni
Seminars in nuclear medicine
41
Citations
1
Influential Citations
Abstract
Non-Hodgkin lymphomas represents a heterogeneous group of lymphoproliferative disorders characterized by different clinical courses, varying from indolent to highly aggressive. 18F-FDG-PET/CT is the current state-of-the-art diagnostic imaging, for the staging, restaging and evaluation of response to treatment in lymphomas with avidity for 18F-FDG, despite it is not routinely recommended for surveillance. PET-based response criteria (using five-point Deauville Score) are nowadays uniformly applied in FDG-avid lymphomas. In this review, a comprehensive overview of the role of 18F-FDG-PET in Non-Hodgkin lymphomas is provided, at each relevant point of patient management, particularly focusing on recent advances on diffuse large B-cell lymphoma and follicular lymphoma, with brief updates also on other histotypes (such as marginal zone, mantle cell, primary mediastinal- B cell lymphoma and T cell lymphoma). PET-derived semiquantitative factors useful for patient stratification and prognostication and emerging radiomics research are also presented.
18F-FDG-PET/CT is a valuable diagnostic imaging tool for staging, restaging, and evaluating response to treatment in non-Hodgkin lymphomas, with recent advances in diffuse large B-cell and follicular lymphoma.
Full text analysis coming soon...